Catalyst Biosciences, Inc.
611 Gateway Blvd.
South San Francisco
About Catalyst Biosciences, Inc.
We are a research and clinical development biopharmaceutical company focused on addressing unmet needs in rare hemostasis and complement-mediated disorders. Our protease engineering platform includes two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; and a partnered preclinical development program with Biogen for dry age-related macular degeneration (“AMD”). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.
162 articles with Catalyst Biosciences, Inc.
Catalyst Biosciences Reports Third Quarter 2017 Operating & Financial Results and Provides Corporate Update
Cash, cash equivalents and short-term investments, as of Sept. 30, 2017, were $27.5 million.
Catalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of Directors
Ms. Hunt was most recently vice president, New Product Gene Therapy, Neuroscience, Oncology, Ophthalmology at Shire.
Catalyst Biosciences Granted FDA Orphan Drug Designation For Subcutaneous Recombinant Human Factor IX Variant For Treatment Of Hemophilia B
Catalyst Biosciences Announces Successful Completion Of First Subcutaneous Dosing Cohort In Ongoing Hemophilia B Clinical Trial
Catalyst Biosciences Reports Second Quarter 2017 Financial Results And Provides Subcutaneous (SQ) Hemophilia Program Update
Catalyst Biosciences Announces Achievement Of Stable Normal Factor IX Blood Levels In A Preclinical Subcutaneous Dosing Model
Catalyst Biosciences And ISU Abxis Complete Dosing Of First Patient Cohort In Hemophilia B Clinical Trial
Catalyst Biosciences Announces Presentations On Its Next-Generation Subcutaneous Hemophilia Product Candidates At The 2017 International Society On Thrombosis And Haemostasis (ISTH) Meeting
Catalyst Biosciences Announces Closing Of A $20.7 Million Underwritten Public Offering And Full Exercise Of Over-Allotment Option
Catalyst Biosciences Announces IND Approval In South Korea For Next-Generation Subcutaneous Factor IX Program
Catalyst Biosciences Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update